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ISSObjectives: Multimorbidity and frailty are consequences of aging with HIV, yet not
everyone with medical disease is frail. Our objective was to identify factors associated
with frailty in a multimorbid HIV-infected cohort.
Design: Analysis of a prospective, observational, longitudinal cohort.
Methods: Three hundred and thirty-two participants in the medically advanced NNTC
were categorized as frail, prefrail, or robust with the Fried Frailty Index. A series of
logistic regression analyses (first univariate, then multivariable) were conducted to
determine whether medical comorbidities, immunologic and virologic parameters,
and/or neuropsychiatric variables predicted increased odds of frailty.
Results: The mean number of medical comorbidities per participant was 2.7, mean
CD4þ T-cell count was 530 cells/ml, and 77% had undetectable HIV RNA in blood.
Twenty-two percent were frail, 55% prefrail, and 23% robust. Significant predictors of
frailty in multivariable analysis were cognitive diagnosis rendered by Frascati criteria,
depressive symptoms, diabetes mellitus, chronic obstructive pulmonary disease
(COPD), and sex. Men were less likely to be frail than women. Higher odds of frailty
were seen with: symptomatic, but not asymptomatic, cognitive impairment (compared
with cognitive normals); more depressive symptoms; diabetes mellitus; and COPD.
Conclusion: Neuropsychiatric illness increased odds of being frail on a predominantly
physical/motoric measure, but only when symptomatic. Lack of association with
asymptomatic impairment may reflect the importance of functional limitation to frailty,
or possibly a unique resilience phenotype. Understanding why sex and symptomatic
neuropsychiatric illness are associated with frailty will be important in managing HIV-
associated morbidity in aging populations.
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Medical illness accrues with age, yet for each level of
comorbidity burden, individual medical outcomes are
variable. Frailty is a phenotype that accounts for some of
this variability; within each stratum of disability, frailty
predicts survival [1,2]. Adults living with HIV exhibit
frailty more frequently than HIV-negative individuals of
similar age, but whether this increase is a consequence of
HIV itself or of its comorbidities is debated [3,4]. Some
also question the validity of frailty measurement tools in
populations with mean ages under 50 [3,4]. As
combination antiretroviral therapy (cART)-era HIV
populations enter decades for which common frailty
measures were designed, determinants of frailty will be
important to identify in order to optimize
clinical management.
The most widely deployed and validated instrument to
measure frailty in HIV-positive and HIV-negative popula-
tions has been the Fried Frailty Index (FFI), which is
heavily weighted to physical characteristics, but lacks
measures of cognition, disability, and comorbidity [5,6].
Accordingly, studies have investigated the relationship
betweenFFI and theseother components. In the context of
HIV, the Study to Understand the Natural History of HIV
and AIDS in the Era of Effective Therapy (SUN study)
assessed comorbidity burdenby theVeteransAgingCohort
Study (VACS) index [7]. Comorbiditywas related to frailty
and prefrailty, but transitions in frailty status were not
reflected by changes in VACS index values [7]. Multi-
morbidity, defined as three or more medical illnesses, was
correlated with frailty in a sample of people living with
HIV (PLWH) visiting a metabolic clinic in Italy [8]. In a
functionally intact [i.e. without impairments in activities of
daily living (ADL)] subsample from this clinic, cognitive
status assessed by three neuropsychologic tests, and
depressive symptom index was also correlated with frailty
status [9]. In a sample from a tertiary care center inMexico
that excluded severe illnesses, such as COPD and advanced
cardiac disease, frailty was related to functional cognitive
impairments assessedwith theNEUROPSIbattery [10]. In
an AIDS Clinical Trials Group (ACTG) longitudinal
observational study (ACTGA5001), cognitive impairment
was associated with frailty, and when present in combina-
tion, resulted in a greater risk of falls, disability, or death
than either factor alone [11].
To date, no studies have examined the simultaneous
relationships between frailty status and neuropsychiatric
dysfunction, medical illness, and immune and virologic
biomarkers in an aging HIV cohort. As increased medical
illness burden is usually an inevitable consequence of
aging, we sought to determine the factors associated with
frailty in a highly multimorbid sample of aging PLWH.
Analysis of a multimorbid patient population allowed
identification of specific illnesses or factors that increased
the likelihood of frailty when individuals had alreadyattained a state of medical compromise. Furthermore, as
cognitive abnormalities without functional impairment
(asymptomatic neurocognitive impairment, ANI) are
common in PLWH, we wanted to ascertain whether ANI
was associated with frailty on a medically morbid
background, as this could have implications for clinical
screening [12].Methods
Patient population
TheNational NeuroAIDSTissue Consortium (NNTC) is
a longitudinal cohort and organ donation study, whose
mission is to serve as a research resource providing tissue
and fluid biospecimens from well characterized HIV-
infected individuals. Participants for this analysis were
enrolled at the four clinical sites of NNTC, located at
Galveston, Texas; Los Angeles, California; NewYorkCity,
New York; and San Diego, California. Participants were
part of the ongoing, longitudinal study conducted under
oversight of each medical center’s local Institutional
Review Board. All participants consented to the use of
their data for the purposes of HIVand neuroHIV research.
All informed consent procedures included tests of
comprehension to ensure cognitively impaired participants
were able to consent. Criteria for entry into the NNTC
study include willingness to be an organ donor upon
demise, and neuromedical conditions for which adequate
or curative therapy is unavailable, thus enriching the cohort
for significant medical morbidity. Qualifying medical
conditions include illnesses, such as solid organ or
hematologic cancers, advanced liver disease, and significant
cardiac disease, but are not limited to these categories and
are at the discretion of NNTC site PIs. In the most recent
5-year cycle, advanced age (60 years or older) was added to
the list of qualifying conditions, enabling NNTC to
support a research focus on aging. Exclusion criteria for
NNTC include unwillingness to be a brain donor upon
demise, and age under 18years (the ageof consent fororgan
donation).
Participants were included in this analysis if the central
NNTC database, located at Emmes Corporation in
Rockville, Maryland, contained a complete FFI assess-
ment collected between 2014 and 2018, along with a full
elaboration of neuromedical disorders active at the time of
assessment. Assessments with missing values were not
included. Of 603 participants active in the study, 332 met
this criteria, and additional information from standard-
ized NNTC evaluations was collected and analyzed, as
described below. Analyses were conducted on all
individuals with available data, and not on the basis of
representativeness of the active cohort, as we did not have
any a priori hypotheses to test regarding which factors
would be associated with frailty. At the time of analysis,
the demographic composition of the larger cohort from
CE: Tripti; QAD/AIDS-D-19-00122; Total nos of Pages: 10;
AIDS-D-19-00122
AQ4
AQ5
Frailty in HIV Morgello et al. 3which the sample was selected was: 77% male, 23%
female; 29% African American, 30% Hispanic, 36%
Caucasian, 5% other race; and 20% intravenous drug use
risk for HIV.
Neuromedical assessment
Participants in the NNTC receive a multimodal
evaluation that includes: laboratory analysis to determine
current CD4þ T-cell count and plasma HIVRNA (lower
limit of quantitation was set at 40 copies/ml); review of all
current medications including cART and adherence;
review of medical illnesses, inclusive of hypertension
(HTN), diabetes mellitus, hyperlipidemia, viral hepatitis,
chronic renal disease, cardiac disease, chronic obstructive
pulmonary disease (COPD), non-AIDS defining cancers,
cerebrovascular disease, and lipodystrophy; review of
other medical and behavioral symptoms (as for example,
weight loss, apathy, fever); review of recent tobacco
smoking; and neurologic examination to evaluate signs
and symptoms of distal symmetric polyneuropathy
(DSPN), and other significant neurologic disorders.
Specific medical illnesses for review were selected on the
basis of their general prevalence in HIV, and because they
collectively accounted for themajority of illness burden in
NNTC. Information was collected both from subject
examination, subject interview, and whenever available,
caregiver interview and review of the medical record.
Neurobehavioral assessment
The NNTC neuropsychological test battery has been
previously published; in brief, a battery of tests is
administered to examine global cognitive function and
the following seven putative cognitive domains: learning;
memory; abstraction/executive functioning; speed of
information processing; verbal fluency; working mem-
ory; and motor [13]. Global and domain T scores are
calculated and used to derive clinical ratings. Functional
impacts are assessed through a modified Lawton and
Brody ADL questionnaire and the Patient’s Assessment of
Own Functioning Inventory (PAOFI), and cognitive
diagnoses are assigned at clinical sites by experienced
neuropsychologists according to the research nosology for
diagnosis of HIV-associated neurocognitive disorders
(HAND) established in Frascati [14]. This nosology
results in the following sub-categories: asymptomatic
neurocognitive impairment (ANI), mild neurocognitive
disorder (MND), HIV-associated dementia (HAD), and
cognitive impairment because of other causes (NPI-O).
Cognitive assessments were utilized only if they occurred
in the same study visit as the FFI and neuromedical
assessment; for 16 individuals, a Frascati diagnosis was not
available in this interval. A structured psychiatric
interview (the Composite International Diagnostic
Interview version 2.1) is conducted, and depressive
symptoms quantified by administration of the Beck
Depression Inventory (BDI) version 2. Depressive
symptom scores were utilized only if they occurred in
the same study visit as the FFI and neuromedicalassessment; for 17 individuals, a BDI score was not
available in this interval.
Frailty assessment
Administration of the FFI at each site was standardized,
and presence or absence of criteria in its five dimensions
(weight loss, exhaustion, grip strength, physical activity,
timed walk) were recorded. Subjects were classified as frail
when they had three or more positive criteria; prefrail
with one or two criteria; and robust when no criteria
were present.
Statistical modeling and analysis
Frailty status was modeled as an ordinal outcome.
Cumulative logistic regression analysis (SAS 9.4 procedure
LOGISTIC) was used to determine statistical significance,
odds ratios (ORs), and 95% confidence intervals (CIs) for
associations between potential risk factors and all frailty
outcomes. Each factor was initiallymodeled in a univariate
setting against frailty status; factors significant at P 0.10 or
less were retained for a multivariable model. In the
multivariable model, factors were removed via backward
elimination until all remaining factors were statistically
significant at P 0.05 or less. ORs and 95% CIs were
computed for these factors for each frailty outcomemodel.
Analyses were not adjusted for multiple comparisons.
Potential risk factors assessed in the initial univariate
analyses included: age, race/ethnicity, sex, IVDU/sexual
risk factor for HIV acquisition, current and nadir CD4þ
T-cell count, plasma HIV RNA, medical illnesses
(described above), smoking, presence of DSPN, cognitive
diagnosis rendered via Frascati criteria, depressive symp-
tom score from the BDI, use of antidepressant medication,
BMI, literacy level assessed by the Wide Range
Achievement Test – version 3 (WRAT-3), and study site.
Secondary analyses included: tests of association with
individual components of the FFI; tests of association
between each nonnormal Frascati diagnosis vs. unim-
paired; a univariate analysis of global T-score on frailty
outcomes; and a multivariable analysis of individual
domainT-scores without adjustments for other factors. As
with other multivariable models, factors were removed
via backward elimination until all remaining factors were
significant at P less than 0.05.Results
Cohort characteristics
The study population was demographically diverse: there
was relatively equal distribution of African American,
Hispanic, and Caucasian race/ethnicity, and 28% were
women. Although most of the population had a low nadir
CD4þT-cell count, the mean current CD4þT-cell count
was 530 cells/ml. Median plasma HIV RNA was
undetectable (77% of the sample). There was a significant
CE: Tripti; QAD/AIDS-D-19-00122; Total nos of Pages: 10;
AIDS-D-19-00122
AQ6
4 AIDS 2019, Vol 00 No 00
Table 1. Subject characteristics.
Total Robust Prefrail Frail P
Sample size, N (%) 332 78 (23%) 181 (55%) 73 (22%) n/a
Mean age (SD) 59.7 (8.9) 58.9 (9.4) 59.5 (8.2) 60.8 (9.9) 0.36
Male sex 72% 85% 71% 63% <0.01
Race/ethnicity 0.5
African American 29% 27% 33% 21%
Hispanic 32% 35% 28% 38%
Caucasian 34% 33% 33% 37%
Other 5% 5% 6% 4%
IVDU risk 23% 21% 21% 29% 0.17
Mean current CD4þ (SD) 530 (299) 489 (299) 552 (314) 520 (257) 0.29
Median nadir CD4þ [IQR] 50 [8–180] 45 [6–145] 65 [7–190] 50 [12–149] 0.55
Median log plasma HIV load [IQR] 1.6 [1.6–1.6] 1.6 [1.6–1.6] 1.6 [1.6–1.6] 1.6 [1.6–1.6] 0.93
Tobacco smoking 46% 35% 52% 44% 0.03
Hypertension 46% 45% 44% 53% 0.36
Diabetes mellitus 20% 6% 23% 27% <0.01
Hyperlipidemia 48% 50% 49% 47% 0.91
Viral hepatitis 21% 22% 19% 23% 0.76
Chronic renal disease 10% 9% 8% 15% 0.25
Cardiac disease 20% 19% 18% 25% 0.45
Chronic obstructive pulmonary disease 15% 6% 16% 22% 0.03
Cerebrovascular disease 17% 10% 19% 18% 0.23
Non-AIDS defining cancer 14% 13% 12% 21% 0.17
Lipodystrophy 11% 10% 13% 8% 0.57
Peripheral neuropathy 58% 51% 58% 69% 0.15
BMI (mean) 27.1 (6.4) 25.7 (4.6) 27.6 (7.2) 27.5 (5.7) 0.07
WRAT-3 raw score (mean) 44.8 (9.0) 44.3 (8.5) 44.9 (9.2) 45.0 (9.1) 0.88
Beck Depression Inventory (median) 8 [2–16] 3 [0–9] 8 [2–16] 16 [7–22] <0.01 AQ11
Antidepressant medication use 38% 30% 37% 46% 0.12
Cognitive diagnosis <0.01
Normal 35% 47% 35% 21%
Asymptomatic impairment (ANI) 14% 24% 15% 3%
Mild neurocognitive disorder (MND) 21% 16% 20% 29%
HIV-associated dementia (HAD) 11% 3% 11% 21%
Impairment because of other causes (NPI-O) 19% 10% 19% 26%
Percentages represent within frailty category totals. IQR, interquartile range.burden of medical comorbidities, with an average of 2.7
medical conditions per person (median 3, IQR [1–4]).
Almost one-half of the sample smoked, had hypertension,
and hyperlipidemia, and over one-half displayed DSPN.
Depressive symptoms were generally within the minimal
to mild range; 38% of the sample was actively prescribed
antidepressant medication. Thirty-five percent of the
sample was cognitively normal, with ANI in 14% and
symptomatic cognitive impairments in 51% (21% MND,
11% HAD, 19% NPI-O) (Table 1).
Associations with overall frailty
Twenty-two percent of the population was frail, 55%
prefrail, and 23% robust. The frequency of abnormal FFI
components included: 15% weight loss, 40% exhaustion,
35%decreased grip strength, 29% reduced physical activity,
and 30% abnormal timed walk. In univariate analyses,
overall frailty status was associated with sex, diabetes
mellitus, COPD, depressive symptoms, and cognitive
diagnosis at the P 0.01 or less level; with DSPN and use of
antidepressant medication at the P 0.05 or less level; and
withBMI and cancer diagnosis atP value 0.10 or less. In the
multivariable model, female sex [OR for men 0.58 (95%
CI: 0.35–0.97), P¼ 0.04], more depressive symptoms
[OR 1.07 per unit BDI (1.05–1.10), P< 0.01], cognitive
abnormality [symptomatic impairment vs. normalcognition OR 2.35 (1.39–3.99), P< 0.01], and the
presence of diabetes mellitus [OR 1.81 (1.02–3.22),
P¼ 0.04] or COPD [OR 1.94 (1.03–3.66), P¼ 0.04)
were associated with frailty (model r2 0.27, P< 0.01). Viral
suppression had no effect in the model. The proportional
odds assumptionwasmet (P¼ 0.51). Twenty-nine percent
of women were frail in contrast to 19% of men; 30% of
thosewith diabetes mellitus were frail in contrast to 20% of
those without; 32% of those with COPD were frail in
contrast to 20% of thosewithout; themean BDI in the frail
was 15.9 in contrast to 5.4 in the robust (38%of thosewith a
BDI score14 – the threshold for mild depression – were
frail comparedwith 14%of thosewithBDI < 14); and 32%
of thosewith symptomatic cognitive impairmentwere frail
in contrast to 13% of cognitive normals (Tables 1 and 2).
Associations with frailty components
In multivariable analysis (Table 2), depressive symptoms
had the most consistent associations with FFI compo-
nents, significant in all except grip strength. Other factors
significantly associated with FFI components after
multivariable analysis were for the most part conceptually
congruent: for example, weight loss was associated with
smoking and cancer, worse physical activity and
exhaustion with increased BMI, and worse physical
activity with COPD.
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.Neurobehavioral associations with frailty
As neurobehavioral abnormalities had the greatest and
most consistent associations with frailty and individual
FFI components, the next set of analyses examined these
associations. First, for the 104 individuals who had a BDI
value in the range of depression (BDI 14), the use of
antidepressant medication (55% of this sub-sample of 104)
was not associated with a greater or lesser percentage
of frailty.
We then examined, which cognitive diagnoses displayed
associations with frailty, and within the entire range of
diagnoses, whether any particular neuropsychological
domains (particularly motor domain, given the physical
emphasis of FFI) accounted for significant associations.
With regard to diagnoses, only symptomatic cognitive
abnormalities, and not asymptomatic, were associated
with frailty [ORs: 2.6 (MND), 5.2 (HAD), and 3.0 (NPI-
O), all P values< 0.01] (Table 3 and Fig. 1). Individuals
with ANI could not be distinguished from those with
normal cognition with regard to the odds of being frail, or
with regard to the odds of abnormality on any individual
frailty component (Table 3). Those with ANI, while
accounting for 14% of the overall sample, accounted for
only 3% of those who were frail, whereas all other
cognitive categories (including normal) accounted for
over 20% of those with frailty (Table 1). The group with
ANI could not be distinguished from other cognitive
categories on the basis of their number of medical
comorbidities. With regard to depressive symptoms, they
were similar to both the cognitively normal group and
those with NPI-O (mean BDI score 8.6, 9.4, and 7.0 for
normal, NPI-O, and ANI, respectively), with more
depressive symptoms in MND (mean score 14.3) and
HAD (mean score 15.1) (overall ANOVA P< 0.01). The
group with ANI had a similar proportion of women
compared with other cognitive categories (27.9%), but
displayed low prevalence of diabetes mellitus (11.6%) and
COPD (4.7%).
Global T scores were associated with frailty and all its
components except weight loss (higher T scores indicate
better function; significant odds ratios ranged from 0.94
to 0.97, with P values 0.02). In the model predicting
overall frailty using neuropsychological domain scores
(but not the global score), only motor domain remained
significant (OR 0.95 [95% CI 0.94–0.97], P<.01); that
is, other domains did not make independent contribu-
tions to frailty when the motor score was accounted for.
Domain associations with individual frailty components
are reported in Table 3.
Sex and frailty
As women had greater odds of being frail when all factors
were considered, we examined sex differences in the
sample to gain insight into this association. Althoughmost
of the women (74%) were located in the New York
NNTC site, there was no site-specific association with
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Table 3. Cognitive associations with frailty and its components.
Frailty component OR (95% CI)
Cognitive diagnosis
(reference: normal)
Frailty OR
(95% CI)
Weight
loss Exhaustion
Physical
activity Timed walk Grip strength
ANI NS NS NS NS NS NS
MND 2.6 (1.4–3.8)b NS 2.6 (1.4–4.8)b NS NS 2.0 (1.0–3.9)a
HAD 5.2 (2.4–11.2)c NS 2.6 (1.2–5.7)a 4.4 (1.9–9.9)c 2.3 (1.0–5.2)a 2.5 (1.1–5.6)a
NPI-O 3.0 (1.6–5.8)c NS NS NS 2.4 (1.2–4.8)a 2.5 (1.3–5.0)b
Cognitive Domain T
score
Global T Scored 0.94 (0.92–0.97)c NS 0.96 (0.93–0.99)b 0.96 (0.93–0.99)b 0.94 (0.91–0.97)c 0.97 (0.94–0.99)a
Abstraction executive
function domain
NS 0.97
(0.94–1.00)a
NS NS NS NS
Memory domain NS NS 0.96 (0.94–0.99)b NS NS NS
Verbal fluency domain NS NS NS 0.97 (0.95–0.99)b NS NS
Motor domain 0.95 (0.94–0.97)c NS NS NS 0.94 (0.92–0.97)c 0.96 (0.94–0.98)c
ANI, asymptomatic neurocognitive impairment; HAD, HIV-associated dementia; MND, mild neurocognitive disorder; NPI-O, cognitive
impairment because of other causes; NS, not significant at P less than 0.05; OR, odds ratio.
aFactor significant at 0.01<P<0.05.
bFactor significant at 0.001<P<0.01.
cFactor significant at P less than 0.001.
dGlobal T score was modeled individually, and not in conjunction with domain scores.frailty status. Women were more often African American
(43 vs. 23%) and less often Caucasian (18 vs. 40%) than
men (P< 0.01), but race/ethnicity was not associated
with frailty. Women in this sample had higher CD4þFig. 1. Distribution of frailty phenotypes by cognitive diagnosis.
within each diagnostic cognitive category. NL: Cognitively norm
neurocognitive disorder; HAD: HIV-associated dementia; NPI-O:T-cell counts and nadirs than men [CD4þ T-cell count
617 (31 SEM) vs. 496 (19 SEM) cells/mm, P< 0.01;
nadir 151 (17 SEM) cells/mm vs. 102 (10 SEM) cells/
mm, P< 0.01)]; again, factors not associated with frailty.Percentage of individuals with frail, pre-frail, or robust status
al; ANI: asymptomatic neurocognitive disorder; MND: mild
cognitive impairment due to other (non HIV) causes.
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(33 vs. 15%, P¼ 0.03), and higher BMI [29.9 (0.6 SEM)
vs. 26.1 (0.4 SEM), P< 0.01].Discussion
Frailty is a useful construct across diverse medical
conditions and populations, as it is an indicator of
decreased physiologic reserve predicting morbidity and
mortality in the face of stressors, and can be used to guide
therapy for medical disease [1,2,15]. It is thought that
HIV is an independent risk factor for frailty, supported by
observations of increased prevalence in HIV cohorts
equivalent to older HIV-negative populations [3,16].
However, PLWH also experience rates of medical
illnesses comparable with older HIV negative adults,
and medical multimorbidity is associated with frailty in
many populations regardless of serostatus [4,8,17].
Accordingly, the purpose of this study was to evaluate
conditions associated with frailty within the context of
multimorbidity using data from the NNTC cohort,
which is a population selected for serious
medical disorders.
In our study, neuropsychiatric illness, manifested by
depressive symptoms and functional cognitive
impairment, was significantly associated with frailty and
its components. No consensus currently exists for an
operational definition of frailty, and many have suggested
that measures of mental health should be included [18].
Our findings support this suggestion, and are consistent
with prior studies in HIV demonstrating an association
between neuropsychiatric abnormality and frailty status
[9,10]. Although the underlying mechanism of this
association cannot be determined in our study, prior
studies have demonstrated an association between motor
abnormality (and with particular relevance to frailty,
abnormal gait) and cognitive impairment, both in PLWH
and HIV-negative populations [19–21]. In turn, motor
and cognitive abnormalities may be correlated with
cerebral white matter disease on neuroimaging [22–24].
Thus, it could be hypothesized that cerebral disorders
impacting connectivity between brain regions via white
matter abnormality form a common basis for both motor
aspects of frailty and abnormal cognition.
Our study also demonstrates that asymptomatic cognitive
impairments are not associated with frailty; lack of
association between ANI and frailty has been previously
noted in a population from Mexico City [10]. Although
the group with ANI in our study had a low prevalence of
frailty, they also had low frequencies of other frailty-
associated factors, such as diabetes mellitus, COPD, and
depressive symptoms. There is controversy surrounding
ANI; some suggest that mild disorders based solely on
cognitive testing may represent a form of false positiveHAND diagnosis; others, that individuals with ANI have
a unique neurobiology manifesting an increased risk of
progression to symptomatic HAND [25–29]. It is also
possible that individuals with ANI have an abnormal
neurobiology dissimilar to other forms of HAND.
Pertinent to a hypothesis implicating white matter
abnormality in the generation of motor deficits and
frailty, a recent study demonstrated that neuroradio-
graphic white matter abnormalities in ANI could be
distinguished from patterns in cognitive normals and in
MND [29]. Pertinent to frailty measures, individuals with
ANI may not display HIV-associated motor abnormali-
ties. In a study of motor correlates of HAND, ANI was
similar to cognitive normal in its lack of motor
manifestations, whereas all forms of syndromic HAND
displayed greater motor impairments [19]. However, it is
also possible that ANI represents a resilience phenotype in
the face of a deleterious neurobiological process in the
continuum of HAND. These may be individuals who
maintain functionality and resist frailty, despite a
significant burden of HIV-associated brain disease.
Continued monitoring of our cohort over time should
determine whether individuals with ANI show adverse
medical and cognitive outcomes, or progression in their
frailty phenotypes.
With regard to other cognitive diagnoses, individuals
with the most severe form of impairment (HAD)
displayed the greatest odds of frailty, and with the
exception of weight loss, pervasive association with all
FFI components. The milder MND and NPI-O had
smaller odds ratios for frailty phenotype, shared an
association with grip strength, and differed with regard to
associations with exhaustion and timed walk.
Frailty in our cohort was also characterized by a pervasive
relationship with depressive symptoms. Antidepressant
medication did not appear to influence this relationship.
The association with depressive symptoms was seen not
only with overall frailty phenotype but alsowith all frailty
components except grip strength. The significance of
this association is unclear; depressive phenomena are
common correlates of a wide spectrum of neurodegen-
erative disorders, but are also encountered with medical
illness and loss of physical function. Whether this
association reflects a causative or reactive phenomenon,
or is simply a correlation in the absence of a primary
pathogenetic mechanism, is unclear. Regardless of
pathogenesis, the association of neurobehavioral phe-
nomena (cognition, depression) with frailty in HIV
suggests that these should be accounted for in future
studies of frailty conducted with regard to single medical
disease outcomes.
With regard to the diverse medical disorders encountered
in our population, diabetes mellitus and COPD were
independently associated with frailty. In the National
Health and Nutrition Examination Survey (NHANES),
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association has received significant attention [30]. It was
observed that individuals with COPD had more than
double the number of medical comorbidities than those
without [30]. In our cohort individuals with COPD had
significantly more medical illnesses than those without
(4.4 vs. 2.4, P< 0.01). However, COPD was not unique:
the same was true for every medical condition examined.
For example, individuals with renal disease in the NNTC
had an average of 4.5 medical illnesses in comparison to
2.5 in those without; yet, renal disease did not increase the
odds of frailty. The association of diabetes mellitus and
frailty has been previously observed, and is hypothesized
to reflect an ‘accelerated aging’ process in this disorder, or
alternatively, complications, such as renal dysfunction
[31]. In our cohort, renal disease was not a plausible
mechanistic pathway for frailty, and in the absence of
biomarkers, we cannot comment on ‘accelerated aging’.
Finally, women in our cohort had greater odds of being
frail than men, which is similar to general populations,
where female sex is associated with frailty [32]. In the
Women’s Interagency HIV Study (WIHS), it has been
suggested that social and behavioral risk factors are
important in the occurrence of frailty [32]. The WIHS is
not selected for medical morbidity, with an overall frailty
prevalence of 10%, less than half of what is seen in the
women of NNTC. The NNTC study was not designed
to examine social or cultural/behavioral factors, and this is
an important area for future investigation, as issues, such as
socioeconomic status, healthcare access and utilization,
and other behaviors and belief systems, could play a role in
the development of frailty. Alternatively, it is possible that
biological factors not routinely ascertained in NNTC
could play a role, such as hormonal status, bone mineral
density, and a more general burden of central nervous
system (CNS) active medications, such as antipsychotics,
sedatives, and anxiolytics. Further study is warranted to
explain this sex disparity.
In summary, the NNTC cohort provides a unique
opportunity to study frailty in the context of medical
multimorbidity, and demonstrates the importance of
symptomatic neuropsychiatric dysfunction to the frailty
phenotype. It also raises questions with regard to why
women and particular medical illnesses have increased
odds of frailty, and suggests that further study will be
necessary to determine if there are modifiable aspects of
these associations that can improve outcomes for adults
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